<ENAMEX TYPE="ORGANIZATION">Syntex Corp.</ENAMEX> said a U.S. district court in <ENAMEX TYPE="LOCATION">New Jersey</ENAMEX> ruled that a generic drug sold by a rival to treat psoriasis and other skin disorders infringed upon a <ENAMEX TYPE="LOCATION">Syntex</ENAMEX> patent for its Lidex cream products. <ENAMEX TYPE="ORGANIZATION">Syntex</ENAMEX> said that as a result of the ruling against <ENAMEX TYPE="ORGANIZATION">T.J. Roaco Ltd.</ENAMEX>, it would seek ``full compensation'' for the infringement at a trial ordered by the court on Nov. 6.
<ENAMEX TYPE="ORGANIZATION">Syntex</ENAMEX>, a health-care company based in <ENAMEX TYPE="LOCATION">Palo Alto</ENAMEX>, <ENAMEX TYPE="LOCATION">Calif.</ENAMEX>, declined to estimate damages. A company spokesman said the ruling sends ``a message that <ENAMEX TYPE="ORGANIZATION">Syntex</ENAMEX> will vigorously enforce its patent against distributors.''
<ENAMEX TYPE="ORGANIZATION">T.J. Roaco</ENAMEX> is a drug distribution concern with its headquarters in <ENAMEX TYPE="LOCATION">New York</ENAMEX> and its principal operations in <ENAMEX TYPE="LOCATION">Toronto</ENAMEX>. Officials couldn't be reached for comment on the ruling.
